23,534views
00:00 / 00:00
FNP3 - exam 2
Crohn disease
Ulcerative colitis
Diverticulosis and diverticulitis
Jaundice
Cirrhosis
Non-alcoholic fatty liver disease
Alcohol-induced liver disease
Hepatitis
Acute pancreatitis
Chronic pancreatitis
Diverticular disease: Pathology review
Gastrointestinal bleeding: Pathology review
Pancreatitis: Pathology review
Cirrhosis: Pathology review
Non-Hodgkin lymphoma
Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Coagulation disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Direct factor inhibitors
Anticoagulants: Warfarin
Cortisol
Cushing syndrome
Hyperaldosteronism
Hypocalcemia
Hypercalcemia
Acromegaly
Precocious puberty
Coarctation of the aorta
Pheochromocytoma
Deep vein thrombosis
Tetralogy of Fallot
Patent ductus arteriosus
Ventricular septal defect
Atrial septal defect
Atrial fibrillation
Tricuspid valve disease
Mitral valve disease
Pulmonary valve disease
Aortic valve disease
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Heart failure
Myocarditis
Neonatal jaundice: Clinical (To be retired)
Polycythemia vera (NORD)
0 / 11 complete
0 / 3 complete
of complete
of complete
Laboratory value | Result |
Hemoglobin | 19.0 g/dL |
Hematocrit | 57% |
Erythrocytes | 7.2 million/mm3 |
Leukocytes | 12,900/mm3 |
Platelets | 440,000/mm3 |
2022
2021
2020
2019
2018
2017
2016
polycythemia vera p. 441
polycythemia vera p. 441
polycythemia vera p. 441
Evan Debevec-McKenney
Stefan Stoisavljevic, MD
In polycythemia vera, there are increased blood cell levels due to overproduction by the bone marrow, which is a soft tissue found within the bones.
Normally, about 45% of the total blood volume is made up of erythrocytes, or red blood cells, and their main function is to carry oxygen to tissues and bring carbon dioxide to the lungs so it can be expired. This value is called the hematocrit.
In polycythemia vera there’s an increase in red blood cell production.
It typically begins with a mutation in a single hematopoietic stem cell, which gives rise to red blood cells, white blood cells, and platelets.
In 90 percent of the affected individuals there is a mutation of the Janus Kinase 2 or JAK2 gene.
Normally, the kidneys produce erythropoietin which is a hormone that binds to receptors on the hematopoietic stem cells and activates JAK2 gene.
When that happens, it causes the cell to divide and thus produce more blood cells.
However, when there’s a mutation, it keeps JAK2 gene activated, and these cells are able to divide even in the absence of erythropoietin.
The mutated cells proliferate, and rapidly become the predominant hematopoietic cells in the bone marrow.
In time these cells start to die out and that’s when scar tissue forms.
At that point, the bone marrow can no longer produce blood cells, leading to anemia or low red blood cell levels, thrombocytopenia or low platelet levels, and leukopenia or low white blood cell levels. This is known as the spent phase.
And once the disease is in the spent phase, it’s really a different disease altogether - at that point it’s myelofibrosis.
The most common symptoms of polycythemia vera are fatigue, dizziness, increased sweating, redness in the face, blurred vision, and itchy skin especially after a hot shower.
Itchiness develops due to the increased number of basophils and mast cells which contain histamine that causes itching when released.
Polycythemia vera is a bone marrow disorder in which there is an overproduction of blood cells, often caused by a JAK2 mutation within hematopoietic cells in the bone marrow. It can lead to elevated hemoglobin and hematocrit and predispose an individual to develop blood clots. Symptoms may include fatigue, weakness, headaches, dizziness, itching, and abdominal pain. Treatment may include medications to lower blood cell formation, and prevention of blood clots, phlebotomy, and radiation therapy.
Copyright © 2023 Elsevier, except certain content provided by third parties
Cookies are used by this site.
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.